Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

  • George Pentheroudakis1Email author,
  • Vassiliki Kotoula2, 3,
  • Wendy De Roock4,
  • George Kouvatseas5,
  • Pavlos Papakostas6,
  • Thomas Makatsoris7,
  • Demetris Papamichael8,
  • Ioannis Xanthakis9,
  • Joseph Sgouros10,
  • Despina Televantou3,
  • Georgia Kafiri11,
  • Athanassios C Tsamandas12,
  • Evangelia Razis13,
  • Eleni Galani14,
  • Dimitrios Bafaloukos15,
  • Ioannis Efstratiou16,
  • Iliada Bompolaki17,
  • Dimitrios Pectasides18,
  • Nicholas Pavlidis1,
  • Sabine Tejpar4 and
  • George Fountzilas9
BMC Cancer201313:49

DOI: 10.1186/1471-2407-13-49

Received: 1 September 2012

Accepted: 30 January 2013

Published: 2 February 2013

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
1 Sep 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
8 Oct 2012 Reviewed Reviewer Report - Jeffrey Evans
27 Oct 2012 Reviewed Reviewer Report - Murali Bashyam
14 Nov 2012 Author responded Author comments - George Pentheroudakis
Resubmission - Version 3
14 Nov 2012 Submitted Manuscript version 3
2 Dec 2012 Reviewed Reviewer Report - Murali Bashyam
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
30 Jan 2013 Editorially accepted
2 Feb 2013 Article published 10.1186/1471-2407-13-49

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Medical Oncology, Ioannina University Hospital
(2)
Department of Pathology, Aristotle University of Thessaloniki School of Medicine
(3)
Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine
(4)
Department of Oncology, Ziekenhuis Oost-Limburg
(5)
Health Data Specialists Ltd
(6)
Department of Medical Oncology, “Hippokration” Hospital
(7)
Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School
(8)
Bank of Cyprus Oncology Center
(9)
Department of Medical Oncology, “Papageorgiou” Hospital, Aristotle University of Thessaloniki School of Medicine
(10)
Third Department of Medical Oncology, “Agii Anargiri” Cancer Hospital
(11)
Department of Pathology, Ippokration Hospital
(12)
Department of Pathology, University Hospital, University of Patras Medical School
(13)
Third Department of Medical Oncology, “Hygeia” Hospital
(14)
Second Department of Medical Oncology, “Metropolitan” Hospital
(15)
First Department of Medical Oncology, “Metropolitan” Hospital
(16)
Department of Pathology, “Papageorgiou” Hospital
(17)
Oncology Department, General Hospital of Chania
(18)
Oncology Section, Second Department of Internal Medicine, “Hippokration” Hospital

Advertisement